Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

EADV 25: Sanofi’s brivekimig in Phase IIa HS trial

Summary by Clinical Trials Arena
As well as HS, Sanofi's brivekimig is being investigated in patients with glomerulonephritis, type 1 diabetes, UC and Crohn’s disease.The post EADV 25: Sanofi’s brivekimig success in Phase IIa HS trial appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

dermatologytimes.comdermatologytimes.com

Sanofi Announces Positive Phase 2a Results for Brivekimig in HS

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa, offering hope for effective treatment options at EADV 2025.

Read Full Article
Clinical Trials ArenaClinical Trials Arena

EADV 25: Sanofi’s brivekimig in Phase IIa HS trial

As well as HS, Sanofi's brivekimig is being investigated in patients with glomerulonephritis, type 1 diabetes, UC and Crohn’s disease.The post EADV 25: Sanofi’s brivekimig success in Phase IIa HS trial appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Wednesday, September 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Brive-La-Gaillarde icon

Brive-La-Gaillarde

News
For You
SearchBlindspotLocal